Listing 13.23 covers ovarian, fallopian, uterine, cervical, vulvar, and vaginal cancer. Small cell ovarian auto-qualifies under Paragraph A. Ovarian 20,180 new US cases + 12,730 deaths 2026, uterine 68,510 + 13,860, cervical 12,890 + 3,860. BRCA1/2 + HRD testing for ovarian, MMR for endometrial, PD-L1 for cervical, FR-alpha for ovarian. PARP maintenance (olaparib SOLO-1, niraparib PRIMA, olaparib + bev PAOLA-1), bevacizumab GOG-0218, mirvetuximab MIRASOL for FR-alpha+ platinum-resistant, dostarlimab + chemo RUBY dMMR endometrial, pembro + lenvatinib KEYNOTE-775, pembro + chemo +/- bev KEYNOTE-826 cervical, tisotumab vedotin innovaTV 204. Radical hysterectomy vs pelvic exenteration + lymphedema.
Read the full article →